Prosecution Insights
Last updated: October 01, 2026

Examiner: SCHWECHTER, BRANDON ROSS

Tech Center 1700 • Art Units: 1674 1681 1797

This examiner grants 0% of resolved cases

Analysis

Brandon Ross Schwechter is an examiner in Tech Center 1700 and Art Unit 1674. He has 1 resolved case. The allowance rate for this examiner is 0.0 percent. This 0.0 percent rate reflects the outcome of the single case in the current data set. Practitioners should note that with only 1 resolved case, the statistical significance of this rate is limited.

The interview lift is 0.0 percent. This value indicates that there is no recorded change in allowance probability associated with interviews in this examiner's history. Because the allowance rate is already stated, the interview lift provides a consistent reflection of the current case outcomes. This suggests that applicants may need to wait for more data to evaluate the effectiveness of oral discussions.

The median days to allowance is 1229. This 1229-day figure represents the time elapsed for the prosecution of the cases in this docket. Applicants can use this 1229-day duration as a preliminary estimate for the length of the patent acquisition process. The combination of 1 resolved case and a 1229-day median provides an initial look at the prosecution environment in Art Unit 1674.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

0.0%
Allow Rate
-65.0% vs TC avg
22
Total Applications
+0.0%
Interview Lift
1229
Avg Prosecution Days
Based on 1 resolved cases, 2023–2026

Rejection Statute Breakdown

3.3%
§101 Eligibility
23.1%
§102 Novelty
26.4%
§103 Obviousness
45.1%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18036602 USE OF ANNEXIN V TO IMPROVE THE PURITY, SOLUBILITY AND LONG-TERM STABILITY OF PHAGE SUSPENSIONS Non-Final OA The Board of Trustees of the Leland Stanford Junior University
18355108 Macrophage Stimulating 1 Receptor (MST1R) Variants And Uses Thereof Final Rejection Regeneron Pharmaceuticals, Inc.
18262543 PEPTIDE FOR PREVENTING AND TREATING FIBROSIS Non-Final OA SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
17732347 MULTISPECIFIC ANTIBODIES Non-Final OA Hoffmann-La Roche Inc.
18557834 COMPOSITIONS AND METHODS OF TREATING SEPSIS IN PATIENTS USING ANTI-LIGHT ANTIBODIES Non-Final OA THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
18173358 COMPOSITIONS AND METHODS FOR PROMOTING HAIR GROWTH Non-Final OA Duke University

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month